A poster presentation at the 2023 International Conference on Alzheimers and Parkinsons Diseases and Related Neurological Disorders (AD/PD) highlighted positive results from one such trial, the Phase II ELAD study, which assessed Novo Nordisks liraglutide in mild to moderate Alzheimers
Copper Tripeptide-1 (GHK-Cu) helps promote firmer, healthier-looking skin
Drawing from common best practices, the experience should feel reliable, evenly paced, and designed with clarity in mind
was supported by a Pels Family Center Fellowship
Flavonoids and gut health
A balanced approach, one that incorporates both the benefits of NSAIDs and strategies to support overall health, can help individuals make informed choices while minimizing potential risks